Publication: Nuevos sistemas de liberación controlada de tolcapona para el tratamiento de la enfermedad de Parkinson
Loading...
Files
Official URL
Full text at PDC
Publication Date
2022-08-10
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La enfermedad de Parkinson (EP) es un trastorno neurodegenerativo complejo y de presentación heterogénea. Aunque aún no se dispone de ningún fármaco que cure la enfermedad, existen agentes para el control sintomático en cada una de sus fases, tratando de mantener en lo posible la calidad de vida de los pacientes. Además, dado que es el trastorno neurodegenerativo más frecuente tras la enfermedad de Alzheimer y que su factor de riesgo principal es la edad, la enfermedad de Parkinson supone, cada vez más, un reto de salud pública. La tolcapona es un inhibidor de la catecol-O-metiltransferasa (COMT) empleado, junto con levodopa, en el control de las fluctuaciones motoras de la EP. La inhibición selectiva y reversible de COMT conduce a una reducción del catabolismo de levodopa a 3-O-metildopa, resultando en una mayor disponibilidad de dopamina en el cerebro, lo que permite una reducción de la dosis diaria total de levodopa...
Parkinson's disease (PD) is a complex neurodegenerative disorder with a heterogeneous presentation. To date there is no cure for the disease however, there are several drugs that can act controlling the symptoms along the progression of the disease in order to maintain the quality of life of the patients. Furthermore, given that it is the second most common neurodegenerative disorder after Alzheimer's disease, and that its main risk factor is age, Parkinson's disease is increasingly posing a public health challenge.Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that is administered with levodopa to control motor fluctuations in PD. Selective and reversible inhibition of COMT leads to a reduction in the catabolism of levodopa to 3-O-methyldopa, resulting in increased availability of dopamine in the brain, thereby allowing for a reduction of total daily dose of levodopa...
Parkinson's disease (PD) is a complex neurodegenerative disorder with a heterogeneous presentation. To date there is no cure for the disease however, there are several drugs that can act controlling the symptoms along the progression of the disease in order to maintain the quality of life of the patients. Furthermore, given that it is the second most common neurodegenerative disorder after Alzheimer's disease, and that its main risk factor is age, Parkinson's disease is increasingly posing a public health challenge.Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that is administered with levodopa to control motor fluctuations in PD. Selective and reversible inhibition of COMT leads to a reduction in the catabolism of levodopa to 3-O-methyldopa, resulting in increased availability of dopamine in the brain, thereby allowing for a reduction of total daily dose of levodopa...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 17-03-2022